The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle
NCT ID: NCT01015144
Last Updated: 2009-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
OBSERVATIONAL
2007-02-28
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin
Tulip
Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
No statin
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tulip
Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who signed informed consent
* patients with dilated cardiomyopathy (according ESC 2007)
* patients who had no significant coronary artery stenoses \>30% on cardiac catheterization
Exclusion Criteria
* congenital heart disease
* acquired valvular disease except for mitral incompetence secondary to left ventricular dilatation
* New York Heart Association (NYHA) functional class IV
* statin treatment
* preserved hyperactivity of aminotransferases with unexplained etiology,
* muscle disorders which might cause drug-induced myopathy,
* uncontrolled diabetes,
* liver diseases,
* creatinine level \> 2 mg/dl and/or GFR\<30ml/min,
* abuse of alcohol or drugs,
* chronic inflammatory diseases,
* pregnancy or lactation,
* severe hypothyroidism,
* immunosuppressive treatment,
* operation or severe injury during last month
* vaccination during last 3 months
* heart stimulation device or implantable cardioverter defibrillator
* or who didn't write conscious consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Lodz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UM Lodz
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agata Bielecka-Dabrowa, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Hypertension UM Lodz
Maciej Banach, Assoc. Prof.
Role: STUDY_DIRECTOR
Department of Hypertension UM Lodz
References
Explore related publications, articles, or registry entries linked to this study.
Bielecka-Dabrowa A, Wierzbicka M, Dabrowa M, Goch A. New methods in laboratory diagnostics of dilated cardiomyopathy. Cardiol J. 2008;15(4):388-95.
Bielecka-Dabrowa A, Wierzbicka M, Goch JH. [Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target]. Wiad Lek. 2007;60(9-10):433-8. Polish.
Bielecka-Dabrowa A, Goch JH, Rysz J, Maciejewski M, Desai R, Aronow WS, Banach M. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. Lipids Health Dis. 2010 Feb 23;9:21. doi: 10.1186/1476-511X-9-21.
Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009 Dec;15(12):MS12-23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
502-11-585
Identifier Type: -
Identifier Source: org_study_id